Exacerbations of asthma are likely to be due to an increase in airway inflammation. We have studied noninvasive markers of airway inflammation in asthma exacerbations induced by reducing the dose of inhaled corticosteroids. Following a 2-wk run-in period, mild exacerbations were induced in subjects with stable asthma controlled with medium-to high-dose inhaled corticosteroids (beclomethasone dipropionate у 800 g or equivalent daily) by switching them to budesonide 200 g daily given from a dry-powder inhaler (Turbohaler). Fifteen subjects were enrolled and were seen twice weekly for 8 wk after steroid reduction. At each visit, exhaled nitric oxide (NO), and methacholine airway responsiveness were measured and spirometry and sputum induction were performed. Mild exacerbation was defined as: ( 1 ) a decrease in morning peak expiratory flow (PEF) of у 20% but Ͻ 30% on at least two consecutive days as compared with the mean for the last 7 d of the run-in period; ( 2 ) awakening on two consecutive nights because of asthma; or ( 3 ) increased use of a short-acting ␤ 2 -agonist to eight or more puffs daily. Eight subjects did not develop exacerbations during the 8-wk study, whereas seven subjects developed mild exacerbations at Week 4 (n ϭ 1), Week 6 (n ϭ 1), and Week 8 (n ϭ 5). The only significant difference between these two groups at baseline was a higher baseline sputum eosinophil count in subjects with subsequent exacerbations (p Ͻ 0.05). The increases in sputum eosinophils and exhaled NO were correlated with decreases in airway function, including decreases in morning PEF and FEV 1 . However, multiple regression analysis suggested that the change in sputum eosinophils is a potentially useful marker in predicting loss of asthma control reflected by loss of airway function. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. 
Asthma is a chronic inflammatory disorder of the airways, and long-term therapy for it is therefore directed at suppressing airway inflammation (1, 2) . Ideally, adequate suppression of inflammation should be maintained throughout the course of therapy. Assessment of asthma severity and the effectiveness of treatment should therefore be guided directly by the degree of airway inflammation. This is inappropriate in clinical practice, since bronchoscopy is required to obtain samples of lower airway tissue. Because of the invasiveness of bronchoscopic procedures, the counting of inflammatory cells and measuring their activity in airway biopsies can be used to assess airway inflammation only for research purposes.
Assessment of asthma severity and the adequacy of asthma therapy is currently guided by indirect markers, such as lung function and existing asthma symptoms (1, 2) . A major drawback to these markers is their uncertain relationship to the degree of airway inflammation and their ability to be temporarily improved by bronchodilators without controlling underlying inflammation. The use of short-acting ␤ 2 -agonist inhalers for rescue or of long-acting ␤ 2 -agonists may confound measurements of lung function and symptoms and therefore obscure the severity of asthma and the effectiveness of treatment for it. Persistent inflammation has been demonstrated in airway biopsies of asthmatic patients whose treatment was guided by asthma symptoms and lung function (3) .
Recently, interest has been shown in developing relatively less invasive markers for monitoring airway inflammation more directly. It is hoped that asthma therapy guided by monitoring of these noninvasive markers may improve the outcome of treatment. These markers should be able to reflect airway inflammation and its changes in agreement with the findings in airway biopsies. They should be useful for monitoring treatment effectiveness and at the same time be sensitive enough to reflect any worsening of airway inflammation. Among various newer methods being developed for monitoring airway inflammation, sputum induction and measurement of exhaled nitric oxide (NO) seem to be the most promising, as they are reproducible and less invasive, and therefore applicable to sequential measurements. Both methods have been found useful in evaluating the antiinflammatory effects of drugs (4) (5) (6) (7) (8) . However, their usefulness for monitoring loss of asthma control has not been investigated to the same extent. We have previously shown that exhaled NO increases when inhaled corticosteroid treatment is withdrawn at the time of increased symptoms, but the timing of these changes in relationship to exacerbations has not been studied (9) . Similarly, an increase in sputum eosinophil numbers has also been reported after steroid withdrawal (10) , but it is not certain how this relates to changes in exhaled NO.
The aim of our study was to evaluate whether parallel monitoring of eosinophils in induced sputum and of exhaled NO could be useful in reflecting loss of asthma control as indicated by loss of airway function. No prospective studies have compared the changes in both parameters in the same patients in relation to changes in airway function. We also attempted to find a marker that might be useful in identifying asthmatic patients who might be at risk of developing exacerbations of asthma following dose reduction of inhaled corticosteroid.
METHODS

Patients
Patients 18 to 70 yr old with a previous history of asthma and who had been treated with an inhaled corticosteroid for at least 3 mo were enrolled in the study. Asthma was diagnosed from a history of recurrent wheezing and chest tightness and a previous physician diagnosis. This was subsequently confirmed by the presence of airway hyperresponsiveness (AHR) (a provocative concentration of methacholine causing a 20% decrease in FEV 1 [PC 20 ] Ͻ 4 mg/ml). Subjects with stable asthma requiring inhaled corticosteroids at medium to high doses (beclomethasone у 800 g or equivalent daily by pressurized metereddose inhaler [MDI] ) to maintain asthma control were recruited. FEV 1 at baseline had to be more than 70% of predicted. For stable asthma, all of the following were required: peak flow (PF) variability Ͻ 20% during a 2-wk run-in period, use of an inhaled ␤ 2 -agonist at not more than four puffs per day, no nocturnal awakening due to asthma, and no changes in frequency or intensity of asthma symptoms or use of medications in the previous 3 mo. No subjects had a history of upper respiratory tract infection within the month preceding the study. Subjects gave written informed consent for their participation, and the study was approved by the Ethics Committee of the Royal Brompton Hospital.
Study Design
In order to determine the onset of asthma relapse after corticosteroid dose reduction, the study was conducted in a single-blind manner, including a 2-wk run-in and an 8-wk steroid reduction period. Sixteen subjects were recruited. This was based on the assumption that half of the subjects would have an exacerbation of asthma. Eight subjects with mild exacerbations were required for detection of a 1.5-fold increase in exhaled NO or sputum eosinophils within the group, for an ␣ specification of 0.05 and a ␤ specification of 0.20 (80% power).
At the screening visit, patients completed a questionnaire about their asthma history and current medications. Additionally, skin prick tests and spirometry were performed. Diary cards were issued. The patients' previous corticosteroid inhalers were replaced with budesonide dry-powder inhalers (Turbohalers; AstraZeneca, Lund, Sweden) at equivalent doses given twice daily. Subjects returned 2 wk later (Week 0) for baseline measurements. Subsequent visits were made twice weekly for a total of four visits (Week 2, Week 4, Week 6, and Week 8). At each visit, exhaled NO and methacholine airway responsiveness were measured, and spirometry and sputum induction were performed. At Week 0, all subjects were switched to budesonide delivered from a Turbohaler at a dose of 100 g twice daily, given together with a matched placebo. The number of puffs taken daily was adjusted to match the number used during the run-in period. Subjects were informed that the budesonide dose could be the same or reduced to 200 g daily. The nurses who performed all measurements were blind to the dose of budesonide used.
The study was suspended for individual patients whenever exacerbations occurred or at Week 8 if there had been no exacerbations. A mild exacerbation was defined as: ( 1 ) a decrease in morning PEF of у 20% but Ͻ 30% on at least two consecutive days as compared with the mean of the last 7 d of the run-in period; ( 2 ) awakening on two consecutive nights because of asthma; or ( 3 ) an increase in the use of short-acting inhaled ␤ 2 -agonist to eight or more puffs daily. A severe exacerbation was defined as a decrease in morning PEF to у 30% below the baseline for two consecutive days. Subjects who developed an exacerbation went to the laboratory as soon as possible within the next 24 h for the same investigations as used regularly in the study. If there was a chance of severe bronchospasm (as judged by the investigator or from variability in PF Ͼ 30% or an FEV 1 of less than 60% predicted), the methacholine challenge test was not to be performed. Throughout the study, subjects recorded asthma symptoms including daytime, nighttime, and early morning chest tightness, with a score ranging from 0 to 3 for each symptom (0 ϭ none, 1 ϭ mild, 2 ϭ moderate, 3 ϭ severe). Morning and evening PEF, and the use of shortacting inhaled ␤ 2 -agonist (puffs/day) for rescue, were also recorded. The levels of morning PEF values that indicated mild exacerbations were calculated and are given individually. At each visit, subjects were encouraged to contact the principal investigator, who was accessible on a 24-h basis, as soon as possible if there was a doubt about their asthma status or any criterion of mild exacerbation was reached. Treatment of an exacerbation included oral prednisolone at 40 mg/d for 1 wk and high-dose budesonide from a Turbohaler ( у 800 g/d) as appropriate. All subjects were treated as outpatients, and telephone assessments were made over the following few days. Subjects returned to the laboratory 1 wk after exacerbations, and subsequent visits were arranged as suitable until asthma status was well controlled.
Exhaled NO Measurement
End-exhaled NO was measured with a chemiluminescence analyzer (Model LR2000; Logan Research, Rochester, UK), using a previously described method (11) . In brief, subjects exhaled slowly through a mouthpiece with an exhalation flow of 5 to 6 L/min from TLC over a 30 to 40-s period. NO was sampled from a sidearm attached to the mouthpiece. The mean NO value was taken from the point corresponding to the plateau of the end-exhaled CO 2 reading (5 to 6% CO 2 ) and representing a lower respiratory tract sample. Results of the analyses were computed and graphically displayed on a plot of NO and CO 2 concentrations, pressure, and flow against time. Measurements were made at the same time of day, and factors that might have influenced NO measurement were controlled throughout the study (12) .
Spirometry and Methacholine Responsiveness
FEV 1 and VC were measured at the same time of day through dry spirometry (Vitalograph Ltd., Buckingham, UK). The best value of three maneuvers was expressed as a percentage of the predicted value.
Inhalation methacholine challenge tests were performed with a dosimeter (Mefar, Bovezzo, Italy). Doubling concentrations of methacholine (0.06 to 32 mg/ml) were inhaled at tidal breathing while patients wore a noseclip. A total of five inhalations of each concentration of methacholine were administered (inhalation time: 1 s; breathholding time: 6 s). FEV 1 was measured 2 min after the last inhalation, until there was a decrease in FEV 1 of у 20% compared with the control inhalation (0.9% saline solution) or until the maximal concentration of methacholine was inhaled. The PC 20 for methacholine was calculated by interpolation on a logarithmic dose-response curve; a value of 8 mg/ ml or less indicated AHR (13) .
Morning and evening PEF values (best of three) were measured with a Mini-Wright peak flow meter (Clement Clarke International, Ltd., Harlow, UK).
Sputum Induction and Processing
Sputum was induced through the method described by Keatings and coworkers (6) . Inhaled albuterol at 200 g was given via an MDI at 15 min before sputum induction. After spirometric values were recorded, subjects were instructed to wash their mouths thoroughly with water. They then inhaled nebulized 3.5% saline at room temperature from an ultrasonic nebulizer (DeVilbiss Co., Heston, UK) at the maximum saline output (4 ml/min). The total period of sputum induction was 15 min. Subjects were encouraged to cough deeply at 3-min intervals until the 15-min induction time had been completed. Mouthwashing before each cough was encouraged in order to minimize salivary contamination. The initial sample from the first cough was discarded. Sputum was collected into a 50-ml polypropylene tube, kept at 4 Њ C, and processed within 2 h.
Spirometry was repeated after sputum induction. If there was more than a 15% decrease in FEV 1 , the subject was required to stay for observation until FEV 1 had returned to baseline.
TABLE 2 CHANGES IN CLINICAL MEASURES, SPUTUM EOSINOPHILS, AND EXHALED NO IN ASTHMATIC SUBJECTS WITHOUT AND WITH SUBSEQUENT EXACERBATIONS
Week
Symptom Score Definition of abbreviations : CI ϭ confidence interval; Eos ϭ eosinophils; MornPEF ϭ morning peak expiratory flow; neut ϭ neutrophils; PC 20 ϭ provocative dose of methacholine needed to reduce FEV by 20%; PFvar ϭ peak flow variability; Spt ϭ sputum; Symptom Score ϭ total daily symptom scores (minimum ϭ 0, maximum ϭ 9); TCC ϭ total inflammatory cell count; ND ϭ not done. For sputum processing, 1 ml Hanks' balanced salt solution (HBSS) containing 1% dithiothreitol (DTT) (Sigma Chemicals, Poole, UK) was added to the sputum. The mixture was vortexed and repeatedly aspirated at room temperature until the sputum was homogenized. Samples were left at room temperature for 5 min. Sputum volume was then recorded, the sputum was further diluted with HBSS to a volume of 5 ml, and the preparation was vortexed briefly and centrifuged at 400 ϫ g for 10 min at 4 Њ C. The final concentration of DTT in all specimens was 0.2%.
The cell pellets from the sputum centrifugation were resuspended for total cell counts recorded with on a hemocytometer, using Kimura stain. Slides were prepared by using a Cytospin instrument (Shandon, Runcorn, UK) and were stained with May-Grunwald-Giemsa stain for differential cell counts. All slides were blinded before counting, and at least 400 inflammatory cells were counted in each sample. An adequate sample was defined as having less than 50% squamous epithelial cells in a Cytospin preparation.
Examination of the reproducibility of differential cell counts performed on 18 pairs of samples obtained from the same asthmatic subjects within an interval of 2 wk showed intraclass correlation coefficients of 0.75 for eosinophils, 0.78 for neutrophils, 0.76 for macrophages, and 0.56 for lymphocytes.
Statistical Analysis
The values of morning PEF, total symptom scores, and rescue inhaler use (puffs/day) were averaged from the last 7 d before each visit. Variability in PF was calculated with the following formula: (maximum PEF 20 , and exhaled NO measured at Week 0 were used as baseline values. To determine whether changes in sputum eosinophil counts and exhaled NO accompanied loss of asthma control, the differences of the last-visit measurements from baseline were used for analysis of correlation with Pearson's product-moment technique. The log-transformed values of the change in sputum eosinophil count were used for analysis. Multiple regression analysis (forward) was then applied to examine whether the changes in sputum eosinophil count and exhaled NO could predict loss of asthma control as reflected by the change in morning PEF and FEV 1 . To identify the parameters that might be useful in identifying asthmatic individuals who could be at risk of exacerbations after corticosteroid dose reduction, subjects were classified into two groups according to whether or not they developed an exacerbation, and the differences in these groups' parameters at baseline were compared through the unpaired t test or Mann-Whitney U test for parametric or nonparametric data, respectively.
RESULTS
One subject dropped out of the study after Visit 3 (Week 4) because he was unable to attend for all of the study visits, and was therefore excluded from the analysis. Fifteen subjects completed the study. All subjects were atopic and used albuterol as rescue medication. Patients' clinical characteristics at baseline are summarized in Table 1 . Eight subjects did not develop exacerbations during the 8 wk of the study, whereas seven subjects subsequently developed mild exacerbations at Week 4 (n ϭ 1), Week 6 (n ϭ 1), and Week 8 (n ϭ 5). Three patients (Patients 2, 6, and 7) had exacerbations reflected by a decrease in morning PEF of Ͼ 20%; four patients (Patients 2, 3, 5, and 6) had exacerbations reflected by nocturnal awakening, and one patient (Patient 1) had an exacerbation reflected by the need for eight or more puffs of rescue medication. Six patients with exacerbations (Patients 1 and 3 through 7) had a decrease in FEV 1 у 20%. None had severe exacerbations that required hospital admission. Exacerbations were successfully treated with oral prednisolone. The changes in clinical parameters, lung function, airway responsiveness, exhaled NO, and sputum inflammatory cells over time in the groups with and without exacerbations are summarized in Table 2 . Methacholine PC 20 at the time of exacerbations was not determined in six of seven subjects for safety reasons.
Although there were no significant differences in patient clinical characteristics at baseline between the groups that did and did not develop exacerbations (Table 1) , a significantly higher baseline sputum eosinophil count (p Ͻ 0.05) was found in subjects who developed exacerbations ( Figure 1A ). The median (interquartile range) values were 13.6 (13.9)% and 0.2 (1.4)% for the subjects with and without subsequent exacerbations, respectively. Exhaled NO levels at baseline, however, were not different between the two groups, with values of 11.3 Ϯ 2.3 ppb and 9.1 Ϯ 1.3 ppb (mean Ϯ SEM), respectively, in patients with and without exacerbations ( Figure 1B) . The changes in exhaled NO, sputum eosinophil count, and PF variability after steroid reduction in individual subjects are summarized in Figures 2 and 3 .
The changes in parameter levels measured on the last visit are summarized in Table 3 . Data from both patient groups were pooled for analysis of correlation (Table 4 ). There were significant correlations between the change in sputum eosinophil count with the changes in morning PEF, PF variability, FEV 1 , exhaled NO, and amount of rescue inhaler use; a significant correlation was also found between the change in exhaled NO with the changes in FEV 1 and the amount of rescue inhaler use. Multiple regression analysis (forward) indicated that the change in sputum eosinophil count was more useful than the change in exhaled NO for predicting both the changes in morning PEF and FEV 1 ( Table 5) . We also selected change in FEV 1 as another outcome variable for loss of asthma control, which is characterized by increasing airway obstruction. FEV 1 is more sensitive to airway obstruction and its measurement is more reproducible than measurement of PEF (14) .
DISCUSSION
Exacerbations of asthma are characterized by increasing airway obstruction. We showed that sputum eosinophils and exhaled NO are increased in parallel in association with decreases in morning PEF and FEV 1 , an increase in PF variability, and mild exacerbations of asthma. This suggests the potential use of changes in sputum eosinophil count and exhaled NO as objective markers for monitoring loss of asthma control during corticosteroid stepdown therapy. Monitoring sputum eosinophils may, however, be more accurate than monitoring exhaled NO in reflecting a loss of asthma control. Also, decreasing the dose of inhaled corticosteroids when airway inflammation is insufficiently controlled may lead to an early exacerbation of asthma.
An important goal of asthma treatment is to prevent exacerbations (2) . Inflammation has been assumed to be an important factor underlying exacerbations of asthma and in determining asthma severity. However, few studies have shown increased inflammatory cell numbers during spontaneous exacerbations of asthma (15, 16) . Sputum eosinophilia has been demonstrated in association with mild (10) and severe (7) exacerbations of asthma. However, there is no clear relationship between increased airway inflammation and exacerbations of asthma. Withdrawal from inhaled corticosteroid therapy has been safely used to examine mild exacerbations of asthma (10) . We therefore induced exacerbations of asthma by reducing a medium or high dose of inhaled steroids required for asthma control to a lower dose, and monitored the resulting changes in airway inflammation prospectively. We chose not to reduce the dose gradually, since exacerbations can occur at varying doses of inhaled corticosteroids after variable periods. This may confound any analysis, since each inflammatory parameter may have a different dose-responsiveness and kinetic response to corticosteroid withdrawal. Also, we did not induce exacerbations by withdrawing subjects completely from inhaled steroids, since worsening of asthma in clinical practice usually occurs despite continuous corticosteroid therapy. By using induced sputum, we demonstrated an associated increase in sputum eosinophil numbers with increasing airflow limitation and exacerbations of asthma. Although our study was not done in a double-blind manner, all measurements and sputum differential cell counts were performed by a blinded investigator.
Current evidence indicates that corticosteroids suppress airway inflammation but do not cure its primary cause (17) . Withdrawal from corticosteroid therapy is therefore expected to be associated with a relapse of inflammation and worsening of asthma. However, there is little information on the likeli- hood of asthma relapse after corticosteroid withdrawal. A study involving patients with moderate to severe asthma indicated that in terms of age, disease duration, and the degree of airflow obstruction, patients who developed a worsening of asthma did not differ from those whose asthma remained stable. Among patients with exacerbations, those who were treated with lower doses of inhaled steroids may develop early worsening (18) . Our study indicates that insufficient control of airway inflammation at the time of reduction in the dose of inhaled corticosteroid may lead to an early loss of asthma control and eventually to an exacerbation of asthma. Asthmatic subjects who developed subsequent exacerbations had significantly higher sputum eosinophil counts at baseline, and this was the only marker that distinguished them from those who did not develop exacerbations. Lung function, methacholine PC 20 , exhaled NO, and asthma symptom scores at baseline were not different in these two groups. Moreover, sputum eosinophilia in patients who developed exacerbations persisted throughout subsequent sputum analysis, with a further increase at the time of exacerbations. This suggests that sputum eosinophil numbers may be a reliable marker of the control of airway inflammation. Sequential monitoring of sputum eosinophils could therefore be useful for predicting loss of asthma control after corticosteroid withdrawal.
The role of sputum eosinophils as an accurate marker of asthma severity has been demonstrated previously shown (19) . Monitoring sputum eosinophils has also been shown to be useful in evaluating the antiinflammatory effects of inhaled corticosteroids (4) (5) (6) (7) . Although the method of sputum induction and processing used for this purpose has not yet been standardized, the reliability and validity of the resulting data do not seem to be influenced by any technical differences in methods used (20) . Either sputum selected from the whole expectorate or the whole expectorate itself can be used for analysis. Increased eosinophil numbers in sputum have been previously demonstrated in asthmatic subjects with exacerbations (7, 21) . The increased eosinophil numbers could be mediated by interleukin (IL)-5, a cytokine specific for eosinophil recruitment and activation. IL-5 has been found to be increased in sputum of asthmatic subjects with exacerbations, in association with sputum eosinophilia, and both IL-5 and eosinophil numbers were decreased after corticosteroid treatment, in association with an improvement in airway function (7). Increased sputum eosinophil counts in our patients could have been due to an insufficient dose of budesonide used to inhibit the release of IL-5.
Despite their greater baseline number of sputum eosinophils, subjects who developed subsequent exacerbations of asthma showed no increase in baseline exhaled NO levels. This may indicate a limitation of NO as an accurate marker of the control of inflammation in subjects using inhaled corticosteroids. It may also suggest that NO is more sensitive to the inhibitory effect of corticosteroids than are sputum eosinophil numbers, so that exhaled NO is suppressed while sputum eosinophil numbers remain increased (22) . The rapid increase in NO levels prior to exacerbations suggests that exhaled NO could be more useful in monitoring loss of asthma control. In a previous study involving asthmatic subjects taking high-dose inhaled steroids, exhaled NO was increased by 6 wk after the initial doses were halved, in association with a loss of asthma control (23) . The increase in exhaled NO preceding exacerbations is likely to result from airway inflammation, since exaled NO also increases in normal subjects with upper respiratory tract infections (24) , and in our study was paralleled by an increase in sputum eosinophils. An increase in exhaled NO therefore requires careful interpretation, as it could be nonspecific. We also found that monitoring sputum eosinophil numbers may be more useful than measuring exhaled NO in reflecting loss of airway function. The role of NO in monitoring airway inflammation in asthma requires further long-term studies.
At present, there are no standardized asthma symptom scores. Our symptom scores included nocturnal, early morning, and daytime asthma symptoms. Our study suggests that monitoring both asthma symptoms and the amount of rescue medication required to control symptoms is useful in detecting worsening of airway inflammation, since both measures were increased in parallel with the changes in other objective parameters of asthma instability in our subjects. The sensitivity of asthma symptom scores in reflecting exacerbations of asthma has also been suggested in another study (10) . However, some asthmatic patients may have a reduced perception of their symptoms (25) . Because symptom-score grading is subjective, it should be used as an adjunct to objective markers for monitoring the control of inflammation. Our study also demonstrates the lack of accuracy of symptom scores and rescue medication use in reflecting control of airway inflammation determined by sputum eosinophil numbers. Both were scored as low in some patients despite high sputum eosinophil numbers. This may reflect a blunting of symptom perception.
It has previously been shown that the clinical course of asthma may change without any concomitant change in airway responsiveness (26) . We were unable to demonstrate the usefulness of methacholine PC 20 in reflecting loss of asthma control prior to exacerbations. It has been shown that the dose and duration of inhaled corticosteroid treatment may influence methacholine PC 20 (27, 28) . Exacerbations of asthma may also be associated with sputum neutrophilia (29, 30) . Two of our subjects (Patients 2 and 3) had exacerbations with sputum neutrophilia, but there were no signs or symptoms to suggest infection. Also, there was no change in these subjects' total cell counts or in the macroscopic appearance of their sputum.
The change in morning PEF from an individual patient's personal best reading has been used as the standard method for monitoring exacerbations of asthma. Some asthmatic patients, however, may not reliably monitor their PEF (31) . Measurement of airway function may be confounded by bronchodilator treatment, and particularly by the use of long-acting inhaled ␤ 2 -agonists (5). In these situations, monitoring airway function may be less accurate than monitoring sputum eosinophil numbers, which reflects the control of airway inflammation more directly. Measurement of sputum eosinophil numbers may also be used for establishing adequate control of airway inflammation before an attempt is made to reduce the dose of inhaled corticosteroids, since spirometry may not indicate adequate control of airway inflammation. We previously have shown that in patients with mild asthma, airway function can be normal despite persistent inflammation in the airways (32) , and in the present study we showed that increased sputum eosinophil numbers are found in some patients despite their having normal airway function. Although sputum induction is more complicated than measurement of airway function, it is not difficult. It remains to be established whether asthma therapy with additional guidance from sputum eosinophil counts may reduce the risk of exacerbations and/or hospital admissions for asthma or improve long-term asthma treatment outcome in comparison with conventional monitoring of airway function.
In summary, our study provides prospective evidence that after inhaled steroid dose reduction, exhaled NO and sputum eosinophil numbers are increased in parallel with loss of airway function. Sputum eosinophil numbers may, however, be more useful than exhaled NO in predicting loss of airway function and exacerbations of asthma. 
